Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 7Unknown 3Recruiting 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Other 3Gynecologic 3Endocrine 2Breast 2Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Neuroendocrine Tumors 52Thyroid Neoplasms 19Thyroid Cancer, Papillary 16Carcinoma, Neuroendocrine 16Pheochromocytoma 11Adrenocortical Carcinoma 11Thyroid Carcinoma, Anaplastic 10Gastro-enteropancreatic neuroendocrine tumor 10Small Cell Lung Carcinoma 9Paraganglioma 9Multiple Endocrine Neoplasia Type 1 9Pituitary Neoplasms 8Lung Neoplasms 8Adenoma, Islet Cell 8Sarcoma 7Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Medullary 6Adenocarcinoma, Follicular 6Colorectal Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Merkel Cell 5Carcinoid Tumor 5Somatostatinoma 4Pancreatic Neoplasms 4Neuroblastoma 4Neoplasm Metastasis 4Cholangiocarcinoma 4Carcinoma, Hepatocellular 4

Interventions

relacorilant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Hypertension × Endocrine × Clear all
NCT03604198 2026-04-21

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Corcept Therapeutics

Phase 2 Active not recruiting
125 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

NCT04530916 2025-11-17

WB2020

Colorado State University

Phase 1/2 Active not recruiting
58 enrolled
Endocrine

Cardiovascular Diseases, Hypertension, Multiple Endocrine Neoplasia Type 1, Atherosclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡